Small Sample Sizes and a False Economy for Psychiatric Clinical Trials by Kapur, Shitij & Munafò, Marcus
                          Kapur, S., & Munafò, M. (2019). Small Sample Sizes and a False
Economy for Psychiatric Clinical Trials. JAMA Psychiatry, 76(7), 676-
677. https://doi.org/10.1001/jamapsychiatry.2019.0095
Publisher's PDF, also known as Version of record
Link to published version (if available):
10.1001/jamapsychiatry.2019.0095
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via AMA at
https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2729439 . Please refer to any applicable terms of use
of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Small Sample Sizes and a False Economy
for Psychiatric Clinical Trials
Shitij Kapur, MBBS, PhD, FRCPC; Marcus Munafò, PhD
In 2013, JAMA Psychiatry published an exciting new finding
by Hallak et al1: patients with schizophrenia who were treated
with a single infusion of the antihypertensive agent sodium
nitroprusside showed a dramatic, instantaneous, and sus-
tained improvement in psy-
chotic and negative symp-
toms. The study by Hallak
et al1 was not only double-blind, randomized, and placebo-
controlled, but the authors had also presented a prospective
power analysis, ensured good interrater reliability, and
reported all the relevant aspects of the trial. Understandably,
this study generated tremendous excitement and several
attempts were made to replicate the finding. In this issue of
JAMA Psychiatry, Brown et al2 report an equally systematic
study that fails to replicate the original finding. In fact, the
findings by Brown et al2 join those of 2 other prior studies3,4
that also failed to replicate the original finding. A careful
analysis of the competing studies fails to reveal an obvious
explanation for this discrepancy—except that the original
finding was based on a rather small sample of just 10 patients
per treatment arm.
Failure to reproduce such dramatic findings is neither new,
nor limited to psychiatry. As provocatively claimed by
Ioannidis5 in 2005, perhaps most published studies are in-
deed false. Alert to this possibility, the Academy of Medical Sci-
ences in the United Kingdom published a report on the repro-
ducibility and reliability of biomedical research, and identified
the many causes for the low replicability of published stud-
ies, from deficiencies in the conduct and reporting of studies
to incentive structures that promote publication over rigour.6,7
However, in the matter of the sodium nitroprusside studies the
methods of the studies seem to be strong and the reporting
seems to be thorough. But rigor of conduct and reporting can-
not overcome the challenge of starting with a small number
of patients.
A review of 83 psychiatric intervention studies indicated
that only half had been subject to any attempt at replication.8
Of those that had been subject to an attempt at replication, only
37% replicated the original effect size, while the others either
contradicted the original finding or observed a much smaller
effect. The review clearly showed that, the larger the original
study, the more likely it was to be replicated.
It is a statistical inevitability that (all other things being
equal) smaller studies will provide more imprecise estimates
of any true effect. Therefore, if a number of small studies are
performed, there will be a wider variation of findings (some-
times described as vibration of effects). If many small studies
are conducted, only those that generate a large effect size (and
therefore reach a P value below the conventional 5% thresh-
old) will be published and these findings from studies with a
small sample size are likely to represent inflated effect size
estimates, and at worst, false positives.
Based on this finding it would be easy to recommend larger
sample sizes in general, given evidence that studies in the bio-
medical sciences are usually too small to detect credible or
likely effect sizes.9 But any such general commandment would
be too simplistic. Ultimately, studies should be large enough
to give a sufficiently precise estimate, but not so large as to be
wasteful. Funders and journals increasingly require a justifi-
cation of sample size. However, calculation of sample size is
not a perfect science and requires an estimation of the ex-
pected outcomes in the drug and placebo groups and an esti-
mation of the expected variance. Getting these estimates right
and realistic is at the heart of the matter.
Hallak et al1 predicted an effect size of d = 1.5. How does
this size compare with effect sizes in this field? We provide not
2, but 3 comparators. A study of clinical interventions in medi-
cine and psychiatry across a range of domains indicates a me-
dian observed an effect size of 0.37 for general medicine and
0.41 for psychiatry.10 A review of more than 7000 patients
treated with antipsychotics in randomized clinical trials
showed that the effect size of the newer atypical antipsychot-
ics, compared with placebo, was 0.48.11 Finally, studies of
schizophrenia clinicians show that they consider an improve-
ment from baseline (which includes placebo response plus drug
response) equivalent to an approximate effect size of d = 1.0
to be clinically significant.12 Thus, seen from these 3 perspec-
tives, an expectation of d = 1.5 vs placebo seems rather opti-
mistic. The temptation is understandable. One would like to
discover the big findings, and such an assumption comes with
the payoff that it decreases the number of patients required
by sample size calculators. However, such over-optimism
comes with 2 wasteful consequences: a higher than appropri-
ate chance of a false negative and, in the event of a positive
finding, a higher chance that the positive finding might be a
false positive with an inflated effect.
So, what is the right effect size to aim for? There is not, and
cannot be, a single answer. What seems prudent is that trials
of any new treatment should assume the median observed in
the field (which usually in the range of 0.3-0.5), and those who
hope for a much larger effect size should be required to pro-
vide a strong justification for such optimism. Because, over-
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